• Protocol to express anti-viral...

Treffer: Protocol to express anti-viral nanobodies and antigenic proteins anchored on the bacterial cell surface through the engineering of probiotic Escherichia coli Nissle 1917.

Title:
Protocol to express anti-viral nanobodies and antigenic proteins anchored on the bacterial cell surface through the engineering of probiotic Escherichia coli Nissle 1917.
Authors:
Kamble NS; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA., Canowitz A; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA., Muck N; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA., Kaur K; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA., Kotagiri N; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA. Electronic address: kotaginh@ucmail.uc.edu.
Source:
STAR protocols [STAR Protoc] 2026 Jan 20; Vol. 7 (1), pp. 104341. Date of Electronic Publication: 2026 Jan 20.
Publication Model:
Ahead of Print
Publication Type:
Journal Article
Language:
English
Journal Info:
Publisher: Cell Press Country of Publication: United States NLM ID: 101769501 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-1667 (Electronic) Linking ISSN: 26661667 NLM ISO Abbreviation: STAR Protoc Subsets: MEDLINE
Imprint Name(s):
Original Publication: [Cambridge, MA] : Cell Press, [2020]-
Contributed Indexing:
Keywords: biotechnology and bioengineering; immunology; microbiology
Entry Date(s):
Date Created: 20260122 Latest Revision: 20260122
Update Code:
20260123
DOI:
10.1016/j.xpro.2025.104341
PMID:
41569847
Database:
MEDLINE

Weitere Informationen

Here, we present a protocol to express anti-viral nanobodies or antigenic proteins anchored on the bacterial cell surface through the engineering of probiotic E. coli Nissle 1917 (EcN). We describe steps for bacterial transformation, protein validation, outer membrane vesicle (OMV) isolation, and in vivo administration. We then detail procedures for immunological assessment through ELISA, neutralization assay, and flow cytometry analysis. This protocol can be adapted for different therapeutic targets beyond SARS-CoV-2. For complete details on the use and execution of this protocol, please refer to Kamble et al. <sup>1</sup> .
(Copyright © 2026 The Author(s). Published by Elsevier Inc. All rights reserved.)

Declaration of interests N.S.K. and N.K. have filed a patent application with the US Patent and Trademark Office related to this work.